MAOB and glycogen storage disease VI: Safinamide is primarily approved forParkinson’s disease, but its potential for treating Alzheimer’sdisease is also being explored, particularly due to its mechanisminvolving monoamine oxidase B inhibition and modulation of glutamaterelease.